August 5, 2026
In the autumn of 2005, investigators in New York and New Jersey began pulling apart a scheme that sounds more like a plot from American Horror Story than a case from a modern courtroom.
A company called Biomedical Tissue Services, run by former oral surgeon Michael Mastromarino, had been quietly harvesting bone, skin, tendons, and other tissue from the bodies of the recently dead, corpses lying in funeral homes across the New York area, awaiting burial or cremation [1]. The families had consented to a funeral. They had not consented to this. Cutters working for the operation removed tissue from the bodies, sometimes replacing leg bones with lengths of PVC pipe so that the remains would retain their shape for burial or an open casket [1].
The paperwork that made it all move was fiction. Consent forms were forged. Death certificates were altered. The medical histories attached to the harvested tissue, the records intended to establish whether a donor had cancer, infection, or another disqualifying condition, were falsified [1].
The tissue was then sold to processing companies, which transformed it into grafts and implants used in living patients. By the time the scheme collapsed, thousands of people had reportedly received tissue that had passed through the operation, and prosecutors accused Mastromarino of showing “depraved indifference” by distributing material recovered from donors with cancer and other diseases [2].
The families had consented to a funeral. They had not consented to a man with a bone saw and a book of forged signatures.
The tabloids called them the Brooklyn “body snatchers,” and one of the bodies they had cut apart belonged to broadcaster Alistair Cooke, whose bones were removed and sold before his cremation [1,2]. But the scandal’s real significance was not its ghoulishness. It was what it revealed: that the trade in human tissue depends heavily on traceability, truthful records and consent, and that when every document in the chain is fabricated, even an established oversight system can fail.
The problem did not disappear with Mastromarino. More than a decade later, a Reuters investigation examined a related but legally distinct American market: the non-transplant body-broker industry supplying cadavers and body parts for research, education and surgical training. Reporters found a national trade so lightly regulated in many jurisdictions that they were able to purchase human body parts through the mail [3].
The dignity of the dead, it turned out, still depended heavily on where the body went, what it was being used for and who was responsible for following the paper trail.
New York’s tissue-bank licensing system was already in place before Mastromarino.
Public Health Law Article 43-B, enacted in 1990, gave the state health commissioner authority over tissue banks. New York’s Part 52 regulations subsequently established licensing and operational requirements for entities that collect, process, store or distribute human tissue within the state [4]. The current rules provide that a tissue bank may not acquire, process, store or distribute tissue in New York without a Department of Health licence unless a specified exception applies [4]. The Mastromarino scandal did not create that framework. It exposed how much any framework depends on honest consent records, reliable donor histories, meaningful inspection and enforcement.
New York later strengthened its criminal law as well. In 2010, the state amended its body-stealing provisions to expressly cover the unlawful removal or receipt of tissue, organs and other parts of a deceased person [2]. The licensing rules and the criminal amendment are separate legal developments, but they reflect the same underlying principle: human tissue is not an ordinary commodity, and its movement from the dead to the living must remain traceable.
New York had been counting tissue banks for fifteen years. The body snatchers showed what counting cannot catch when every signature lies.”
That distinction makes the alloclae™ story more interesting, not less. The state did not have to invent a law for injectable cadaver-derived fat. It already had a regulatory system broad enough to ask where the tissue came from, who processed it, who distributed it and whether they were licensed to do so.
Twenty years after Mastromarino, that older system encountered a product no one designing it could have imagined.
If you have been following this series so far, you’ll know that in Part 1 we examined the market GLP-1 drugs helped create for alloclae™, while in Part 2 we looked at the biology of integration and volume retention. In these articles we explained how alloclae™ is manufactured from processed adipose tissue recovered from deceased donors. According to its manufacturer, more than 2,000 patients received alloclae™ injections between its commercial launch in May 2025 and July 2026 [5]. That figure placed alloclae™ squarely in the path of New York’s existing tissue-bank rules: human tissue recovered from the dead, processed outside the state and distributed for implantation into living recipients.
According to court filings reviewed by Business Insider, the New York State Department of Health sent its distributor, Tiger Aesthetics Medical, LLC, several letters between October 2024 and May 2025 stating that it could not grant permission to distribute alloclae™ in the state [6]. The dispute later escalated into litigation. State officials allege that Tiger and affiliated parties distributed alloclae™ in New York without the required licence, including by routing shipments through addresses in New Jersey and Connecticut. In one filing, a state lawyer described the conduct as a “year-long scheme to smuggle” the product into New York [6]. Tiger strongly disputes that characterization and argues that alloclae™ is not the kind of “tissue” subject to the state licensing scheme. The company sued, arguing in part that federal, not state, law governs the product and seeking a declaration that New York’s tissue-bank regulations do not apply to adipose-derived products such as alloClae [5,6].
By June 2026, Tiger had told customers that it would temporarily pause distribution in New York while the litigation proceeded. Some physicians stopped offering the product, while others continued to advertise or administer existing supplies. One clinic described alloclae™ as “revolutionary” directly beneath a notice stating that it was not approved by the New York State Department of Health [6].
One New York health-law attorney interviewed about the dispute said the outcome could go either way. The absence of comparable challenges in other states could support Tiger’s position; entering the New York permitting process and then allegedly distributing the product before receiving authorization could support the state’s [6]. Whether New York’s tissue-bank statute applies to this processed adipose product remains contested.
But it sits on top of a deeper federal question: precisely what regulatory category does alloclae™ belong in?
Tiger describes alloclae™ as a human cell, tissue, and cellular or tissue-based product that does not require pre-market approval because it falls under Section 361 of the Public Health Service Act and 21 CFR Part 1271. This means it is not an FDA-approved drug, device or biologic [5–7], and the degree of oversight under section 361 is not equivalent. The Section 361 pathway imposes requirements involving donor eligibility, communicable-disease screening and testing, registration, processing controls, record keeping and current good tissue practice [7]. It does not require the manufacturer to submit the same product-specific premarket evidence of safety and effectiveness required for an FDA-approved drug, device or licensed biological product.
The absence of premarket approval does not mean the product is unregulated. It means that everything depends on whether the product correctly qualifies for the tissue-only pathway in the first place. Two of the four criteria in 21 CFR 1271.10(a) are especially relevant to alloclae™: minimal manipulation and homologous use [7].
Homologous use asks whether the tissue performs the same basic function in the recipient that it performed in the donor. FDA guidance recognizes cushioning and support as basic functions of adipose tissue and provides examples in which adipose tissue used to provide cushioning or support may constitute homologous use [7].
But the more important question is how the tissue has been processed. For structural tissue, the FDA defines minimal manipulation as processing that does not alter the original characteristics of the tissue that are relevant to its utility for reconstruction, repair or replacement [7]. FDA guidance specifically gives the example of removing cells from adipose tissue to produce a decellularized extracellular matrix and states that this constitutes more than minimal manipulation because the processing alters the tissue’s original relevant characteristics [7]. That example creates an obvious regulatory question for alloclae™, but not an automatic answer.
A tissue product that qualifies under Section 361 avoids product-specific premarket approval. One that does not qualify may require regulation as a drug, device and/or biological product. Everything depends on which side of that line alloClae falls™.
The published characterization of alloclae™ describes a detergent-based process that reduces DNA and free oil while preserving much of the adipose tissue architecture and extracellular matrix [8]. The manufacturer states that the finished product contains no viable cells. That description is similar enough to the FDA’s adipose example to invite scrutiny, but the publicly available information does not establish that the product and the agency’s example are identical in processing, composition or intended function.
Its manufacturer claims that more structural elements remain in their matrix relative to other matrix products, and that alloclae™ therefore qualifies for regulation solely under Section 361. And while a regulator could reasonably ask whether it remains minimally manipulated structural tissue, the FDA has not publicly issued a product-specific approval or classification decision endorsing that position. In 2025, the agency reportedly told Allure that the information available to it was insufficient to determine how alloclae™ should be regulated [9].
There is no settled question with an obvious villain here. It is a classification dispute, the kind that emerges when a novel product reaches patients before the regulatory frameworks have caught up.
It would be easy to file all of this under the macabre and move on: the body snatcher, the “zombie filler,” the lawsuit. But that would miss a professional lesson that is genuinely useful to anyone who builds or evaluates evidence for a living.
alloClae™ is a case study in what happens when a product’s scientific novelty outpaces the certainty of its regulatory identity:
The thread running through this whole series is a single, unglamorous discipline: matching the strength of a claim to the strength of its evidence and matching a product’s marketing to its actual regulatory standing.
“Lunch-break boob job” is a catchy phrase, but the long-term clinical evidence isn’t there yet, and the regulatory record doesn’t back it. Somewhere between the desire to look our best and the appeal of a reassuring label lies the work of reading the guidance, weighing the retention data and, when needed, digging into the court filings. That work is not glamorous. But it’s what separates a product story from a cautionary tale. And it is exactly the kind of scrutiny a scientist-led shop should bring to a claim before the launch, not after the complaint.
This article is educational and non-promotional; nothing here constitutes legal advice. The regulatory classification of processed adipose products is unsettled and fact-specific as of July 2026. Litigation details reflect public reporting on contested court filings available as of July 2026 and should be verified against the primary docket before reliance.
References